SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Castelli Jeff

(Last)

(First)

(Middle)

3675 MARKET STREET

(Street)

PHILADELPHIA

19104

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/21/2022

3. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	304,255⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (right to buy)	⁽²⁾	06/01/2025	Common Stock	50,000	$12.28	D
Stock Options (right to buy)	⁽²⁾	01/04/2026	Common Stock	50,000	$9.03	D
Stock Options (right to buy)	⁽²⁾	01/03/2028	Common Stock	39,762	$15.67	D
Stock Options (right to buy)	⁽³⁾	01/02/2029	Common Stock	82,644	$10.04	D
Stock Options (right to buy)	⁽⁴⁾	01/02/2030	Common Stock	107,575	$9.55	D
Stock Options (right to buy)	⁽⁵⁾	01/04/2031	Common Stock	46,396	$21.78	D
Stock Options (right to buy)	⁽⁶⁾	01/03/2032	Common Stock	108,266	$12.11	D

Explanation of Responses:

1. Includes 161,910 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Amicus common stock.

2. All of the options in this row are fully vested and exercisable as of December 21, 2022.

3. The options reported in this row were granted on January 2, 2019 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 80,896 of such options were fully vested and exercisable and 1,748 remained unvested.

4. The options reported in this row were granted on January 2, 2020 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 78,436 of such options were fully vested and exercisable and 29,139 remained unvested.

5. The options reported in this row were granted on January 4, 2021 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 22,225 of such options were fully vested and exercisable and 24,171 remained unvested.

6. The options reported in this row were granted on January 3, 2022 and will become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 0 of such options were fully vested and exercisable and 108,266 remained unvested.

Remarks:

	/s/ Christian Formica, Attorney-in-Fact	12/30/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.